원료의약품 시장 : 시장 분석 및 예측 - 유형별, 제품별, 서비스별, 기술별, 용도별, 형태별, 프로세스별, 최종 사용자별, 단계별(-2035년)

The global Active Pharmaceutical Ingredient Market is projected to grow from $144.2 billion in 2025 to $273.5 billion by 2035, at a compound annual growth rate (CAGR) of 6.6%. The Active Pharmaceutical Ingredient (API) Market is moderately consolidated, with synthetic APIs accounting for the largest share due to their extensive use in generic medicines, while biotech APIs are gaining momentum through the growth of biologics and specialty therapies. The market is driven by increasing pharmaceutical production, rising demand for innovative medicines, expansion of CDMO services, and investments in API manufacturing capacity. Companies are focusing on supply chain resilience, vertical integration, and advanced manufacturing technologies. For instance, in August 2025, AbbVie announced a $195 million investment to expand its active pharmaceutical ingredient manufacturing capabilities at its North Chicago, Illinois facility, strengthening domestic API production capacity for immunology, oncology, and neuroscience medicines.

Based on Type, the Synthetic APIs segment dominated the Active Pharmaceutical Ingredient (API) market in 2025 due to its established manufacturing ecosystem, cost-effectiveness, and extensive application across a wide range of therapeutic areas. Synthetic APIs are widely used in generic drug production, which accounts for a significant share of global pharmaceutical consumption due to increasing demand for affordable medicines. Their well-established chemical synthesis processes, scalability, regulatory familiarity, and consistent quality make them highly preferred among pharmaceutical manufacturers. The strong presence of large-scale API producers, growing demand for chronic disease medications, and increasing outsourcing of API manufacturing to CDMOs further reinforce the dominance of the synthetic API segment.

Based on Product, the Innovative APIs segment is projected to register the fastest growth during the forecast period, driven by increasing research and development activities focused on novel therapies and advanced drug formulations. The rising prevalence of complex diseases such as cancer, neurological disorders, and autoimmune conditions is increasing demand for innovative APIs that enable targeted and personalized treatments. Growing investments in pharmaceutical innovation, expansion of biologics and specialty drug pipelines, and increasing approvals of breakthrough therapies are accelerating segment growth. Additionally, pharmaceutical companies are focusing on developing differentiated medicines with improved efficacy and safety profiles, further supporting the rapid expansion of innovative APIs globally.

Geographical Overview

Asia-Pacific dominated the Active Pharmaceutical Ingredient (API) market in 2025, supported by its strong pharmaceutical manufacturing ecosystem, large-scale production capabilities, cost advantages, and growing presence of contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs). China and India are the leading contributors due to their extensive API manufacturing infrastructure, availability of skilled workforce, competitive production costs, and significant role in global generic drug supply chains. The region benefits from increasing demand for affordable medicines, rising pharmaceutical exports, and government initiatives aimed at strengthening domestic drug manufacturing capabilities. Additionally, expanding investments in advanced manufacturing technologies and biotechnology are further reinforcing Asia-Pacifics leadership in the global API market.

Asia-Pacific is projected to register the fastest growth during the forecast period, driven by increasing pharmaceutical outsourcing, rising demand for generic and specialty medicines, and expanding healthcare infrastructure across emerging economies. Countries such as India, China, South Korea, and Singapore are witnessing significant investments in API manufacturing facilities, biologics production, and advanced pharmaceutical technologies. The growing prevalence of chronic diseases, increasing healthcare expenditure, and government initiatives supporting local pharmaceutical production are accelerating regional market expansion. Furthermore, the shift toward supply chain diversification and reduced dependence on single-source API suppliers is encouraging multinational pharmaceutical companies to expand partnerships and manufacturing operations across the Asia-Pacific region.

Key Trends and Drivers

Increasing Adoption of Advanced Manufacturing Technologies in API Production:

The Active Pharmaceutical Ingredient (API) market is witnessing a strong trend toward the adoption of advanced manufacturing technologies, including biotechnology-based production, automation, artificial intelligence (AI), and continuous manufacturing processes. These technologies are improving production efficiency, scalability, quality control, and cost optimization across API manufacturing operations. The increasing complexity of drug molecules, rising demand for biologics and specialty medicines, and the need for reliable supply chains are encouraging pharmaceutical companies and CDMOs to invest in advanced production capabilities. Furthermore, the integration of digital technologies and sustainable manufacturing practices is enabling manufacturers to enhance operational performance while meeting evolving regulatory and environmental standards.

Growing Demand for Generic Medicines and Biopharmaceutical Therapies:

The increasing global demand for generic medicines and biopharmaceutical therapies is a major driver of the Active Pharmaceutical Ingredient (API) market. Rising healthcare expenditure, growing prevalence of chronic diseases, and the need for affordable treatment options are accelerating the production of generic drugs, creating sustained demand for high-quality APIs. At the same time, the expansion of biologics, biosimilars, and targeted therapies is increasing the need for advanced biotech-derived APIs. Supportive government initiatives to improve access to essential medicines, patent expirations of branded drugs, and increasing outsourcing of API manufacturing to CDMOs are further contributing to market growth across developed and emerging regions.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by Form
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by End User
• 2.9 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Synthetic
  • 4.1.2 Biotech
  • 4.1.3 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Generic APIs
  • 4.2.2 Innovative APIs
  • 4.2.3 Others
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Contract Development
  • 4.3.2 Contract Manufacturing
  • 4.3.3 Others
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Chemical Synthesis
  • 4.4.2 Biotechnology
  • 4.4.3 Fermentation
  • 4.4.4 Others
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Cardiovascular
  • 4.5.2 Oncology
  • 4.5.3 Neurology
  • 4.5.4 Infectious Diseases
  • 4.5.5 Diabetes
  • 4.5.6 Respiratory
  • 4.5.7 Gastrointestinal
  • 4.5.8 Endocrinology
  • 4.5.9 Dermatology
  • 4.5.10 Others
• 4.6 Market Size & Forecast by Form (2020-2035)
  • 4.6.1 Solid
  • 4.6.2 Liquid
  • 4.6.3 Semi-Solid
  • 4.6.4 Others
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Captive Manufacturing
  • 4.7.2 Contract Manufacturing
  • 4.7.3 Others
• 4.8 Market Size & Forecast by End User (2020-2035)
  • 4.8.1 Pharmaceutical Companies
  • 4.8.2 Biotechnology Companies
  • 4.8.3 Research Laboratories
  • 4.8.4 Others
• 4.9 Market Size & Forecast by Stage (2020-2035)
  • 4.9.1 Clinical
  • 4.9.2 Commercial
  • 4.9.3 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 Form
    • 5.2.1.7 Process
    • 5.2.1.8 End User
    • 5.2.1.9 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 Form
    • 5.2.2.7 Process
    • 5.2.2.8 End User
    • 5.2.2.9 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 Form
    • 5.2.3.7 Process
    • 5.2.3.8 End User
    • 5.2.3.9 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 Form
    • 5.3.1.7 Process
    • 5.3.1.8 End User
    • 5.3.1.9 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 Form
    • 5.3.2.7 Process
    • 5.3.2.8 End User
    • 5.3.2.9 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 Form
    • 5.3.3.7 Process
    • 5.3.3.8 End User
    • 5.3.3.9 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 Form
    • 5.4.1.7 Process
    • 5.4.1.8 End User
    • 5.4.1.9 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 Form
    • 5.4.2.7 Process
    • 5.4.2.8 End User
    • 5.4.2.9 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 Form
    • 5.4.3.7 Process
    • 5.4.3.8 End User
    • 5.4.3.9 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 Form
    • 5.4.4.7 Process
    • 5.4.4.8 End User
    • 5.4.4.9 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 Form
    • 5.4.5.7 Process
    • 5.4.5.8 End User
    • 5.4.5.9 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 Form
    • 5.4.6.7 Process
    • 5.4.6.8 End User
    • 5.4.6.9 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 Form
    • 5.4.7.7 Process
    • 5.4.7.8 End User
    • 5.4.7.9 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 Form
    • 5.5.1.7 Process
    • 5.5.1.8 End User
    • 5.5.1.9 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 Form
    • 5.5.2.7 Process
    • 5.5.2.8 End User
    • 5.5.2.9 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 Form
    • 5.5.3.7 Process
    • 5.5.3.8 End User
    • 5.5.3.9 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 Form
    • 5.5.4.7 Process
    • 5.5.4.8 End User
    • 5.5.4.9 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 Form
    • 5.5.5.7 Process
    • 5.5.5.8 End User
    • 5.5.5.9 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 Form
    • 5.5.6.7 Process
    • 5.5.6.8 End User
    • 5.5.6.9 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 Form
    • 5.6.1.7 Process
    • 5.6.1.8 End User
    • 5.6.1.9 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 Form
    • 5.6.2.7 Process
    • 5.6.2.8 End User
    • 5.6.2.9 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 Form
    • 5.6.3.7 Process
    • 5.6.3.8 End User
    • 5.6.3.9 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 Form
    • 5.6.4.7 Process
    • 5.6.4.8 End User
    • 5.6.4.9 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 Form
    • 5.6.5.7 Process
    • 5.6.5.8 End User
    • 5.6.5.9 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Teva Pharmaceutical Industries
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Sun Pharmaceutical Industries
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Pfizer
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Novartis
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Sanofi
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Roche
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Merck
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Boehringer Ingelheim
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Bayer
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Aurobindo Pharma
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Lupin
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Cipla
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Dr Reddys Laboratories
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Mylan
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 AbbVie
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Eli Lilly and Company
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 GlaxoSmithKline
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 AstraZeneca
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Fresenius
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Amgen
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us